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ORIGINAL ARTICLE

Targeted Inhibition of Calpain Reduces Myocardial
Hypertrophy and Fibrosis in Mouse Models of
Type 1 Diabetes
Ying Li,1,2 Jian Ma,1,2 Huaqing Zhu,1,2 Manpreet Singh,1,3 David Hill,2,4 Peter A. Greer,5,6
J. Malcolm Arnold,2,4 E. Dale Abel,7 and Tianqing Peng1,2,3

OBJECTIVE—Recently we have shown that calpain-1 activation
contributes to cardiomyocyte apoptosis induced by hyperglycemia. This study was undertaken to investigate whether targeted
disruption of calpain would reduce myocardial hypertrophy and
ﬁbrosis in mouse models of type 1 diabetes.
RESEARCH DESIGN AND METHODS—Diabetes in mice was
induced by injection of streptozotocin (STZ), and OVE26 mice
were also used as a type 1 diabetic model. The function of calpain
was genetically manipulated by cardiomyocyte-speciﬁc knockout
Capn4 in mice and the use of calpastatin transgenic mice. Myocardial hypertrophy and ﬁbrosis were investigated 2 and 5 months
after STZ injection or in OVE26 diabetic mice at the age of 5 months.
Cultured isolated adult mouse cardiac ﬁbroblast cells were also
investigated under high glucose conditions.
RESULTS—Calpain activity, cardiomyocyte cross-sectional areas,
and myocardial collagen deposition were signiﬁcantly increased
in both STZ-induced and OVE26 diabetic hearts, and these were
accompanied by elevated expression of hypertrophic and ﬁbrotic
collagen genes. Deﬁciency of Capn4 or overexpression of calpastatin reduced myocardial hypertrophy and ﬁbrosis in both diabetic models, leading to the improvement of myocardial function.
These effects were associated with a normalization of the nuclear
factor of activated T-cell nuclear factor-kB and matrix metalloproteinase (MMP) activities in diabetic hearts. In cultured cardiac
ﬁbroblasts, high glucose–induced proliferation and MMP activities were prevented by calpain inhibition.
CONCLUSIONS—Myocardial hypertrophy and ﬁbrosis in diabetic mice are attenuated by reduction of calpain function. Thus
targeted inhibition of calpain represents a potential novel therapeutic strategy for reversing diabetic cardiomyopathy. Diabetes
60:2985–2994, 2011
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C

ardiovascular complications are the leading cause
of diabetes-related morbidity and mortality (1).
Diabetes not only exacerbates cardiac injury after myocardial infarction or ischemia/reperfusion
(2–4) but also directly damages the heart, leading to a
unique diabetic cardiomyopathy independent of coronary
artery disease, hypertension, and hyperlipidemia (1,5). Diabetes is characterized by hyperglycemia. The correlation
between hyperglycemia and cardiomyopathic changes such
as cardiac hypertrophy, interstitial ﬁbrosis, and apoptosis of
cardiomyocytes is long established (6). However, the underlying cellular mechanisms responsible for these abnormalities remain partially understood.
Calpains are Ca2+-dependent intracellular proteases. Two
of the best characterized calpain species are m-calpain
(calpain-1) and m-calpain (calpain-2). These isoforms are
heterodimers consisting of ;80 kDa catalytic subunits
(encoded by the Capn1 and Capn2 genes, respectively) and
a ;30 kDa regulatory subunit (encoded by Capn4) (7–9).
The regulatory subunit is essential for m- and m-calpain
stability and catalytic activity. Knockout of Capn4 in mice
abolished calpain-1 and calpain-2 activity, resulting in embryonic lethality (10). Calpain-1 and calpain-2 activities are
tightly controlled by the endogenous inhibitor calpastatin.
Calpastatin appears to be speciﬁc for these two calpain
isoforms but does not inhibit any other protease (7). Overexpression of calpastatin has been successfully used to block
calpain activation both in vitro and in vivo (11–14). Although
its precise physiological function is uncertain, calpain plays
a demonstrated role in cardiovascular disease (14,15).
Studies have shown promising improvements in cardiac function after inhibition of calpain activity whether
in infarction or ischemia/reperfusion models (14–17). We
have recently demonstrated that calpain activity increases
in high glucose–treated cardiomyocytes and in short-term
streptozotocin (STZ)-induced diabetes (14). Pharmacological
inhibition of calpain reduced apoptosis in both treatments.
Furthermore, research has uncovered vital roles for calpain
in regulating the activity of nuclear factor of activated
T cells (NFAT) and nuclear factor-kB (NF-kB), two transcription factors frequently implicated in the promotion of
hypertrophy and ﬁbrosis (18–21). Therefore, we hypothesized that inhibition of calpain may have a protective effect
on the myocardium in diabetes. To our knowledge, no study
has previously examined the role of calpain in cardiac hypertrophy and ﬁbrosis in diabetic conditions. Here we show
that cardiomyocyte-speciﬁc calpain deletion or calpastatin
overexpression reduces cardiomyopathy in mouse models
of type 1 diabetes.
DIABETES, VOL. 60, NOVEMBER 2011
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RESEARCH DESIGN AND METHODS
Animals. This investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the U.S. National Institutes of Health (NIH
Publication No. 85–23). All experimental procedures were approved by the
Animal Use Subcommittee at the University of Western Ontario, Canada.
Breeding pairs of C57BL/6 mice and FVB(Cg)-Tg(Ins2-CALM)26OveTg
(Cryaa-Tag)1Ove/PneJ transgenic mice (OVE26), a mouse model of type 1 diabetes, were purchased from the Jackson Laboratory. Mice bearing the targeted
Capn4PZ allele containing loxP sites ﬂanking essential coding exons and mice
with cardiomyocyte-speciﬁc expression of Cre recombinase (Tg-Cre) under the
control of a-myosin heavy chain (a-MHC) were generated as described previously (22,23). Transgenic mice overexpressing calpastatin (Tg-CAST) driven
by cytomegalovirus promoter were provided by Dr. Laurent Baud (the Institut
National de la Santé et de la Recherche Médicale, Paris, France) through the
European Mouse Mutant Archive (11).
Experimental protocol. Diabetes was induced in adult male mice (2 months
old) by consecutive peritoneal injection of streptozotocin (STZ; 50 mg/kg per
day) for 5 days. Seventy-two hours after the last injection of STZ, whole blood
was obtained from the mouse tail-vein and random glucose levels were measured using the OneTouch Ultra 2 blood glucose monitoring system (LifeScan,
Milpitas, CA). Mice were considered diabetic and used for the study only if they
had hyperglycemia ($15 mmol/L) 72 h after STZ injection. Citrate buffer–treated
mice were used as nondiabetic controls (blood glucose ,12 mmol/L). After the
induction of diabetes (2 or 5 months), mice (n = 8–12 in each group) were killed
for the following experiments.
Isolation of cardiac ﬁbroblasts. Cardiac ﬁbroblasts were isolated as described previously (24) with some modiﬁcations. In brief, mouse ventricular
tissues were excised, rinsed with cold PBS, and then placed in isolation buffer.
Individual ventricles were minced and digested for 90 min in isolation buffer
containing collagenase type 2 and dispase-II. Fibroblasts were collected by
centrifugation, resuspended in Dulbecco’s modiﬁed Eagle’s medium containing 10% FBS, and seeded onto tissue culture dishes. All ﬁbroblasts were used
from the ﬁrst two to four generations.
Histological analyses. The collagen contents and cardiomyocyte crosssectional area were assessed as described in our recent report (25).
Calpain activity. Calpain activities were determined by using a ﬂuorescence
substrate N-succinyl-LLVY-AMC (Cedarlane Laboratories) (12–14) and by casein
zymography as described previously (26).
NFAT and NF-kB. NFAT and NF-kB activities were determined by using
ELISA-based transcription factor Filter Plate Assay kits according to the manufacturer’s instructions (Signosis).
Matrix metalloproteinases activity. Global matrix metalloproteinases (MMP),
MMP-2, and MMP-9 activities were assessed by using commercial kits (AnaSpec),
respectively.
Assessment of cell proliferation. Cell growth was evaluated using the 3-(4, 5dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and a DNA
bromodeoxyuridine (BrdU) cell proliferation assay (Millipore) according to the
manufacturer’s instructions.
Real-time RT-PCR. Real-time RT-PCR was performed to analyze mRNA expression for Capn4, b-myosin heavy chain (b-MHC), atrial natriuretic peptide
(ANP), collagen I and III, and GAPDH as described in our recent report (25).
Assessment of cardiac function. Maximal and minimal ﬁrst derivatives of
force (+dF/dtmax and 2dF/dtmin) as the rate of contraction and relaxation were
assessed as described previously (12,25).
In vivo left ventricular pressure–volume measurements. Mice were
anesthetized with ketamine/xylazine cocktail and ventilated. The chest was
opened, and a Scisense mouse PV catheter (FTE-1212B-4518, 1.2F) was directly
inserted into the left ventricle (LV) via the apex to measure LV pressures and
volumes as we described recently (27,28). Data were recorded by the ADVantage
PV System (Model FY997B, London, ON, Canada). All hemodynamic parameters
were analyzed by a LabScribe2 Data Recording Software (CB Sciences, Dover,
NH) according to the manufacturer’s instructions.
Statistical analysis. All data were presented as mean 6 SD. ANOVA followed
by Newman-Keuls test was performed for multigroup comparisons. A value of
P , 0.05 was considered statistically signiﬁcant.

RESULTS

Calpain activities are increased in diabetic hearts. To
establish calpain as a protease of interest in understanding
the mechanisms behind cardiomyopathy in the diabetic
heart, we measured calpain activity in heart tissues from
STZ-injected and OVE26 diabetic mice. Consistent with
our recent report in short-term STZ-induced diabetes (14),
both STZ and OVE26 hearts showed a signiﬁcant increase
2986
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in calpain activity over nondiabetic hearts (Fig. 1A and B).
The activation of calpain was further conﬁrmed by upregulation of cleaved a-spectrin in diabetic hearts (Fig. 1C).
The upregulation of calpain activity was not as a result of
alterations in the ratio of calpain to calpastatin expression because the protein and mRNA levels of calpain-1
and calpain-2 as well as calpastatin were not signiﬁcantly
altered in diabetic hearts (Fig. 1D and Supplementary
Fig. 1). These results conﬁrm the association between increased calpain activity and diabetes.
Generation of cardiac-speciﬁc Capn4 knockout mice.
To investigate the role of calpain, we generated mice with
cardiomyocyte-speciﬁc disruption of calpain by crossing
ﬂoxed Capn4PZ mice with transgenic mice overexpressing
Cre under the control of the a-MHC promoter (Tg-Cre).
All of the mice used in this study, including controls, were
littermates of the same generation. PCR analysis of tail
DNA conﬁrmed untargeted (Capn4+/+), either homozygous
(Capn4PZ/PZ) or heterozygous (Capn4+/PZ) for the ﬂoxed
Capn4 gene, and the Cre transgene (Supplementary Fig. 2A).
Mice homozygous or heterozygous for the ﬂoxed Capn4
gene and positive for the a-MHC-Cre transgene were identiﬁed as potential homozygous (Capn42/2) or heterozygous
knockouts (Capn4+/2), respectively. To conﬁrm decreased
Capn4 expression in the heart, Capn4 mRNA was analyzed
in Capn4+/+ and Capn42/2 mice using primers speciﬁcally
amplifying the deleted region of Capn4 mRNA. Myocardial
Capn4 mRNA was reduced by 78% in Capn42/2 mice, as
compared with Capn4+/+ mice (Fig. 2A and B). In contrast,
Capn4 mRNA levels in lung tissues were similar between
Capn42/2 and Capn4+/+ mice (Fig. 2A and B), supporting
cardiac-speciﬁc Capn4 knockout. To further conﬁrm that
the deletion of Capn4 was restricted in cardiomyocytes, the
mRNA levels of Capn4 were signiﬁcantly decreased in
isolated cardiomyocytes of Capn42/2 mice, whereas their
levels were comparable between Capn42/2 and Capn4+/+
ﬁbroblasts (Fig. 2C). Because the Capn4-encoded regulatory subunit is required for the stability and proteolytic
activities of calpain-1 and calpain-2 catalytic subunits (10),
Capn4 deletion results in the disruption of calpain-1 and
calpain-2 activities. Indeed, casein zymography analysis
of myocardial tissues showed a robust reduction of both
calpain-1 and calpain-2 activities in Capn42/2 compared with
Capn4+/+ mice (Fig. 2D), conﬁrming the functional knockout
of Capn4. Similar to Capn4 mRNA expression, both calpain-1
and calpain-2 activities were not decreased in Capn42/2 lung
tissues (Fig. 2D).
Capn42/2 mice grew normally into adulthood with no
obvious health problems. In nondiabetic mice, there were no
differences in heart weight, body weight, and in Capn4+/+ or
Capn42/2 mice (Supplementary Table 1). Glucose tolerance
test showed no difference between Capn4+/+ and Capn42/2
(Supplementary Fig. 2B). Histological analysis showed no
pathological changes in Capn42/2 hearts (Supplementary
Fig. 2C). These observations suggest that cardiomyocytespeciﬁc deletion of Capn4 is not deleterious to the heart and
rules out potential adverse effects of Cre expression in the
hearts of Capn42/2 mice.
Disruption of calpain reduces myocardial hypertrophy in mouse models of type 1 diabetes. Capn42/2 and
Capn4+/+ mice were rendered diabetic with STZ. Two
months after STZ injection, mice exhibited hyperglycemia,
hyperphagia, polydipsia, and decreased body weight versus vehicle-treated animals. There were no evident differences in body weight, heart weight, and blood glucose
concentration between Capn42/2 and Capn4+/+ diabetic
diabetes.diabetesjournals.org
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FIG. 1. Calpain activity and protein expression in STZ-injected and OVE26 mice. Enzymatic calpain activity was measured in sham and STZ-treated
hearts (A) or wild-type (WT) and OVE26 hearts (B). C: The cleavage of a-spectrin (120/150 KD) was determined in sham and STZ-injected hearts
by Western blot analysis. Top: A representative Western blot for cleaved fragments of a-spectrin from four of eight different hearts in each group;
bottom: quantiﬁcation of cleaved fragments of a-spectrin relative to GAPDH. D: Representative Western blot for calpain-1, calpain-2, and GAPDH
proteins from four of eight hearts in each group (sham and STZ-induced hearts). D1 and D2 are the quantiﬁcation of calpain-1 and calpain-2
protein relative to GAPDH. Data are mean 6 SD; n = 8. KD, kDa. *P < 0.05 vs. sham or WT.

mice (Supplementary Table 1). Consistent with our recent
report (25), histological analysis of cardiomyocyte crosssectional areas in wild-type mice revealed increased
cardiomyocyte size in diabetic versus nondiabetic hearts,
indicative of cardiomyocyte hypertrophy. However, cardiomyocyte sizes were not increased in diabetic Capn42/2
hearts (Fig. 3A). Furthermore, gene expression measurements of diabetic hearts showed upregulation of both ANP
and b-MHC mRNA (Fig. 3B and C), providing further evidence of a hypertrophic phenotype. Although both genes
were also upregulated in Capn42/2 diabetic hearts, those
increases were signiﬁcantly reduced relative to wild-type
mice (Fig. 3B and C). Interestingly, there were no differences
in cardiomyocyte size and hypertrophic gene expression
when comparing Capn42/2 and Capn4+/+ nondiabetic hearts
(Fig. 3B and C). These results demonstrated that Capn4
knockout prevents myocardial hypertrophy in a mouse
model of STZ-induced type 1 diabetes. Deletion of Capn4
also decreased myocardial caspase-3 activity (Fig. 3D) and
cytoplasmic histone-associated DNA fragments (Supplementary Fig. 3), suggesting a reduction of apoptosis, which
diabetes.diabetesjournals.org

is consistent with our recent report (14). Similarly, 5 months
after STZ injection, cardiomyocyte size and hypertrophic
gene expression were reduced in Capn42/2 compared with
Capn4+/+ hearts (Supplementary Fig. 4A and B), suggesting
that the protective effects of Capn4 deletion may be sustained in diabetic cardiomyopathy.
Calpain-1 and calpain-2 activities are tightly and speciﬁcally
regulated by calpastatin (8). Overexpression of calpastatin
has been successfully used to block calpain activation
both in vitro and in vivo (11–14). To further understand the
role of calpain in diabetic cardiac hypertrophy, we rendered
transgenic calpastatin mice (Tg-CAST) and their wild-type
littermates diabetic by STZ treatment and assessed cardiac
hypertrophic changes 2 months after STZ injection. In nondiabetic mice, there were no differences in cardiomyocyte
sizes and hypertrophic gene expression in hearts of
Tg-CAST and wild-type mice (Fig. 3E–G). In diabetic mice,
overexpression of calpastatin did not correlate with altered
blood glucose levels and body and heart weight (Supplementary Table 1); however, diabetes-induced increases in
cardiomyocyte cross-sectional areas, ANP and b-MHC
DIABETES, VOL. 60, NOVEMBER 2011
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FIG. 2. Characterization of mice with cardiac-speciﬁc Capn4 knockout. A: Representative RT-PCR for Cre and Capn4 mRNA from two of six mice
in each group. Cre mRNA was detected in Capn42/2 hearts (lanes 3 and 4). Levels of Capn4 mRNA were signiﬁcantly reduced in Capn42/2 hearts.
In contrast, the Capn4 mRNA was not decreased in Capn42/2 lungs. B: Capn4 mRNA was quantiﬁed by real-time RT-PCR in Capn4+/+ and Capn42/2
hearts (B1) and lung tissues (B2). C1 and C2 are the quantiﬁcation of Capn4 mRNA in isolated cardiomyocytes (C1) and cardiac ﬁbroblasts (C2)
from Capn4+/+ and Capn42/2 mice. D: Representative casein zymography for calpain-1 and calpain-2 activities from two of six hearts and lungs,
respectively, showing downregulation of calpain-1 and calpain-2 activities in Capn42/2 hearts but not in lungs. Data are mean 6 SD; n = 5–9. *P <
0.05 vs. +/+. OD, optical density.

expression, and caspase-3 activity were signiﬁcantly attenuated in Tg-CAST compared with wild-type mice (Fig. 3E–H).
These results further argue that inhibition of calpain reduces
myocardial hypertrophy in STZ-induced diabetic mice.
To rule out the possibility that STZ treatment had systemic
actions independent of b-cell destruction, we repeated these
experiments in the OVE26 type 1 diabetic mouse model and
crossed them with Tg-CAST mice to inhibit calpain activity.
Expression of transgenic calpastatin in the OVE26 heart was
conﬁrmed by RT-PCR (Supplementary Fig. 5A). At the age of
5 months, cardiomyocyte cross-sectional areas, the levels
of ANP and b-MHC mRNA, and caspase-3 activity were
signiﬁcantly increased in OVE26 mice compared with their
wild-type littermates (Fig. 4A–D), indicative of cardiac
hypertrophy. There were no differences in blood glucose
levels and body and heart weight between OVE26 and
Tg-CAST/OVE26 mice (Supplementary Table 1); however,
the increases in cardiomyocyte cross-sectional areas, ANP
and b-MHC expression, and caspase-3 in OVE26 hearts
were normalized in Tg-CAST/OVE26 mice (Fig. 4A–D). These
2988
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results in the OVE26 model further support the antihypertrophic effect of calpain inhibition in type 1 diabetes.
To explore potential downstream signaling in calpainmediated myocardial hypertrophy, we focused on two
transcription factors, NFAT and NF-kB, which play central
roles in the regulation of cardiac hypertrophy (18,29–32). It
is generally accepted that calpain-dependent activation of
the serine/threonine protein phosphatase calcineurin controls NFAT activity in cardiomyocytes (18). Studies also
suggest that calpain mediates degradation of the cytosolic
NF-kB inhibitor, inhibitor k Ba (IkBa), a step that is a prerequisite in the activation of NF-kB (33). In this regard, we
measured the activities of both NF-kB and NFAT in OVE26
and Capn42/2 diabetic hearts. When compared with the
nondiabetic heart of wild-type or Tg-CAST mice, the activities of both NF-kB and NFAT were increased in OVE26
and STZ-injected Capn4+/+ hearts. However, overexpression
of calpastatin in Tg-CAST/OVE26 mice and Capn4 deletion in Capn42/2 STZ mice correlated with signiﬁcantly
lowered NF-kB and NFAT activities relative to OVE26 and
diabetes.diabetesjournals.org
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FIG. 3. Assessment of cardiac hypertrophy in diabetic Capn42/2
(knockout [KO]) and Tg-CAST mice. Cardiac hypertrophy was determined by measuring cardiomyocyte cross-sectional areas and
hypertrophic gene expression (ANP and b-MHC). A–D: Deﬁciency of
Capn4 reduced cardiomyocyte cross-sectional areas (A), the mRNA
levels of ANP (B) and b-MHC (C ), and caspase-3 activity (D) in diabetic Capn42/2 hearts. E–H: Cardiomyocyte cross-sectional areas
(E), the mRNA levels of ANP (F ) and b-MHC (G), and caspase-3
activity (H) were decreased in diabetic Tg-CAST hearts. Data are
mean 6 SD; n = 8. *P < 0.05 vs. sham in wild-type (WT); #P < 0.05 vs.
STZ in WT.

STZ-injected Capn4+/+ hearts (Fig. 4E–H). These results
suggest that the calpain/calpastatin system may be involved
in the activation of NF-kB and NFAT pathways in the complex regulation of cardiac hypertrophy in diabetic hearts.
Calpain is required for myocardial ﬁbrosis in mouse
models of type 1 diabetes. Myocardial ﬁbrosis is commonly observed in diabetic cardiomyopathy and is characterized by excessive production and accumulation of
extracellular collagen (1,34). To assess ﬁbrosis, myocardial
tissues were stained with picrosirius red to highlight collagen. Ratios of collagen area to total area were measured.
Deposition of collagen was increased in STZ-induced diabetic hearts; however, Capn4 deletion in Capn42/2 mice
and calpastatin overexpression in Tg-CAST mice correlated
with a signiﬁcant reduction in those levels after STZ injection (Fig. 5A–C). In line with altered collagen deposition,
deletion of Capn4 and overexpression of calpastatin lowered the mRNA levels of collagens I and III in diabetic
Capn42/2 and Tg-CAST hearts, respectively (Fig. 5E and F
and Supplementary Fig. 6A). Similarly, this inhibitory effect of calpain deletion on myocardial ﬁbrosis was also
observed 5 months after STZ injection (Supplementary
Fig. 4C–E). Thus, inhibition or targeted disruption of calpain
prevented myocardial ﬁbrosis in the STZ-induced mouse
model of type 1 diabetes.
MMPs play key roles in maintenance and degradation of
the extracellular matrix (ECM), contributing to the process
diabetes.diabetesjournals.org

FIG. 4. Assessment of cardiac hypertrophy in OVE26 mice. A–D: Cardiomyocyte cross-sectional areas, the mRNA levels of ANP (B) and
b-MHC (C), and caspase-3 activity (D) increased in OVE26 relative to
wild-type (WT) hearts, but were reduced in Tg-CAST/OVE26 mice. E–H:
NFAT and NF-kB activities were increased in OVE26 and STZ-injected
WT hearts but were reduced in Tg-CAST/OVE26 and Capn4 knockout
(KO) hearts. Data are mean 6 SD; n = 6–8. *P < 0.05 vs. WT; #P < 0.05
vs. OVE26 or STZ in WT.

of myocardial ﬁbrosis (35), so we next measured MMP
activity in the myocardium. STZ-induced diabetes correlated with 34% elevation in total MMP activity, but this
increase was signiﬁcantly reduced in diabetic Tg-CAST
and Capn42/2 mice (Fig. 6A and D). Because MMP-2 and
MMP-9 are the most important MMPs in the regulation of
myocardial remodeling, we measured their activities in the
diabetic heart. Similarly, both MMP-2 and MMP-9 activities
were reduced in Tg-CAST and Capn42/2 mice (Fig. 6B, C,
E, and F). The role of MMPs is negatively regulated by tissue inhibitors of metalloproteinases (TIMPs). We therefore
also measured TIMP-1 and TIMP-2 expression in the diabetic heart. The mRNA levels of TIMP-1 and TIMP-2 were
signiﬁcantly increased in diabetic Capn42/2 compared with
Capn+/+ mice (Fig. 6H and I). Taken together, our data
suggest that disruption of calpain may inhibit MMP activities through downregulation of TIMP-1 and TIMP-2 in the
diabetic heart.
Inﬂammation plays an important role in myocardial ﬁbrosis. Our recent study demonstrated that expression of
proinﬂammatory cytokines correlates with myocardial ﬁbrosis in the diabetic heart (25). In line with the inhibition
of myocardial ﬁbrosis, deletion of Capn4 signiﬁcantly decreased TNF-a and TGF-b1 expression in diabetic Capn42/2
compared with Capn4+/+ mice (Fig. 7A and B). In addition,
DIABETES, VOL. 60, NOVEMBER 2011
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FIG. 5. Assessment of ﬁbrosis in diabetic hearts. Myocardial collagen deposition was determined by picrosirius red staining and collagen III mRNA
was quantiﬁed by real-time RT-PCR. A: Representative picrosirius red staining for collagen deposition from diabetic Capn42/2 and Capn4+/+ hearts
(red color). Collagen deposition was reduced in hearts of Capn42/2 (knockout [KO]; B), Tg-CAST (C), and Tg-CAST/OVE26 (D) relative
to diabetic wild-type (WT), Capn4+/+ (KO), and OVE26 diabetic mice, respectively. Collagen III mRNA was decreased in diabetic Capn42/2 (E),
Tg-CAST (F), and Tg-CAST/OVE26 mice (G). Data are mean 6 SD; n = 8 to 9. *P < 0.05 vs. sham or nondiabetic WT; #P < 0.05 vs. STZ in WT or
OVE26. (A high-quality color representation of this ﬁgure is available in the online issue.)

the number of mast cells was increased in the diabetic heart,
which was reduced in Capn42/2 mice (Supplementary Fig.
7A and B).
OVE26 mice also displayed myocardial ﬁbrosis as determined by increases in collagen deposition (Fig. 5D),
mRNA levels of collagen I and collagen III (Fig. 5G and
Supplementary Fig. 6B), and elevation of MMP activity
(Fig. 6G). All these indications of ﬁbrosis were normalized
by calpastatin overexpression in Tg-CAST/OVE26 mice.
These results further argue for the protective effects of
calpain inhibition in diabetic hearts in mouse models of
type 1 diabetes.
To gain further insights into the role of calpain in ﬁbrosis, we isolated and cultured cardiac ﬁbroblast cells,
which are the putative mediators of ﬁbrosis. High glucose
(30 mmol/L) was used to mimic the diabetic condition in
cultured ﬁbroblasts. High glucose raised calpain (Fig. 7C)
2990
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and MMP activities (Fig. 7D) as well as cell proliferation
relative to normal glucose (5.5 mmol/L; Fig. 7E and F).
These effects were abrogated by calpain inhibitor-III. Consistently, ﬁbroblasts from Tg-CAST hearts showed much
lower MMP activity and less cell proliferation than those
from wild-type hearts in response to high glucose (Fig. 7D–F).
These effects of calpain inhibition correlated with the
changes of NF-kB activation (Fig. 7G). Further in vivo evidence to support the inhibitory effect of calpain inhibition
on ﬁbroblast proliferation in the diabetic heart were that 1)
a-smooth muscle actin (a-SMA) expression was reduced in
diabetic Capn42/2 compared with Capn4+/+ mice and 2) the
number of noncardiomyocytes was relatively less in diabetic
Capn42/2 than that in Capn4+/+ hearts (Supplementary Fig.
7D and E). Thus, inhibition of MMP activity and reduction of
ﬁbroblast cell proliferation by calpain inhibition may represent
important mechanisms for reducing ﬁbrosis in diabetic hearts.
diabetes.diabetesjournals.org
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FIG. 6. MMP activities and TIMP expression in diabetic hearts. MMP
activities were determined in Capn42/2, Tg-CAST, and OVE26 hearts.
A: MMP activities were increased in diabetic hearts. Overexpression of
calpastatin reduced total MMP activities and MMP-2 and MMP-9 activities in diabetic Tg-CAST hearts (A–C). D–F: Deﬁciency of Capn4
reduced total MMP activities and MMP-2 and MMP-9 activities in
Capn42/2 (knockout [KO]) relative to nondiabetic wild-type (WT)
hearts. G: Total MMP activities were elevated in OVE26 relative to WT
hearts and were decreased in Tg-CAST/OVE26 hearts. H and I: TIMP-1
and TIMP-2 mRNA levels were decreased in Capn42/2 (KO) relative to
nondiabetic WT hearts. Data are mean 6 SD; n = 6–8. *P < 0.05 vs. WT;
#P < 0.05 vs. STZ-treated WT or OVE26.

Myocardial function in mouse model of STZ-induced
type 1 diabetes. Having demonstrated the ability of
calpastatin and cardiac Capn4 deletion to reverse cardiomyocyte hypertrophy and ﬁbrosis in the diabetic myocardium, we performed in vivo LV pressure–volume
measurements and a functional analysis of heart contraction and relaxation using the Langendorff system as an
extension of those results. The hemodynamic parameters
were shown in Supplementary Tables 2 and 3. As expected,
pressure–volume analysis showed signiﬁcant decreases in
maximal positive and minimal negative ﬁrst derivatives
of LV pressure (+dP/dtmax and 2dP/dtmin) and increase
in LV stiffness in diabetic hearts. However, these changes of
2dP/dtmin and stiffness were relatively attenuated in diabetic Capn42/2 and Tg-CAST compared with their wildtype littermates (Fig. 8A–D). Consistently, the decreases of
heart contraction and relaxation were also attenuated in
isolated calpastatin transgenic and Capn4 knockout hearts
after STZ injection (Fig. 8E–H). Taken together, targeted
disruption of calpain preserves myocardial function in diabetic cardiomyopathy of STZ-induced type 1 diabetes.
DISCUSSION

Although calpain activity is elevated in the diabetic heart
(14), its pathophysiological signiﬁcance is incompletely understood. In the current study, we generated novel mouse
diabetes.diabetesjournals.org

FIG. 7. Proinﬂammatory cytokine expression in diabetic Capn4 knockout hearts. Five months after STZ injection, the mRNA levels of TGF-b1
(A) and TNF-a (B) in Capn42/2 (knockout; KO) and Capn4+/+ (wildtype; WT) hearts were determined by real-time RT-PCR. Data are
mean 6 SD from six different hearts in each group. *P < 0.05 vs. WT.
Effects of calpain inhibition on MMP activity and cell proliferation.
Cardiac ﬁbroblast cells were isolated from WT and Tg-CAST mice and
were incubated with normal (NG; 5.5 mmol/L) and high glucose (HG;
30 mmol/L) in the presence and absence of calpain inhibitor-III (10
mmol/L) for 24 h. Calpain activity in ﬁbroblast cells (C) and MMP
activity (D) in culture media were measured. Cell proliferation was
determined by the 3-(4, 5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (E) and BrdU incorporation assay (F).
NF-kB activity was measured in ﬁbroblasts (G; see details in RESEARCH
DESIGN AND METHODS). Data are mean 6 SD from at least three different
cultures. *P < 0.05 vs. NG; #P < 0.05 vs. WT cells cultured in HG.

models including cardiac-speciﬁc Capn4 knockout mice
and OVE26 mice with calpastatin overexpression and investigated the role of calpain in diabetic cardiomyopathy.
We observed that cardiac-speciﬁc deletion of Capn4 and
calpastatin overexpression reduced cardiac hypertrophy
and ﬁbrosis in both STZ-induced and OVE26 type 1 diabetic
mice, leading to the improvement of myocardial function.
Given the fact that both calpastatin overexpression and
Capn4 deletion inhibit only calpain-1 and calpain-2 activity
out of the 14 known mammalian isoforms (7), the current
study reveals a pivotal role for these two calpain isoforms in
diabetic cardiomyopathy.
An important cellular hallmark of diabetic cardiomyopathy is cardiac hypertrophy (1,5,36). In its initial stages, cardiomyocyte enlargement may be an adaptive response
intended to improve ventricular performance (37). However,
sustained hypertrophic growth of the myocardium may be
associated with pathological LV remodeling (37). The role
of calpain in cardiac hypertrophy is poorly understood.
A recent study reported that transgenic overexpression of
calpastatin reduced myocardial hypertrophy in a mouse
model of angiotensin-II–induced hypertension (38), suggesting that calpain may be a contributing factor to cardiac
DIABETES, VOL. 60, NOVEMBER 2011
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FIG. 8. Cardiac function. Tg-CAST, Capn42/2 (knockout [KO]), and
wild-type (WT) mice were injected with STZ. Two (Tg-CAST) or ﬁve
months (Capn42/2) after STZ injection, in vivo hemodynamic measurement was performed. Changes in 2dP/dtmin (A and C) and LV stiffness (B
and D) are shown. Data are mean 6 SD; n = 6–10 per group. *P < 0.05 vs.
WT sham; #P < 0.05 vs. WT STZ. Two months after STZ injection, mouse
hearts were isolated and perfused in a Langendorff system. Contractile
function of the heart was determined. Changes in the rate of contraction
(+dF/dtmax; E and G) and relaxation (2dF/dtmin; F and H) are presented.
Data are mean 6 SD; n = 8 to 9 per group. *P < 0.05 vs. WT sham; #P <
0.05 vs. WT STZ.

hypertrophy. By impeding calpain function we observed a
clear reversal of cardiac hypertrophy in both STZ-induced
and OVE26 type 1 diabetic mice. These data suggest that
calpains may play a role in cardiac hypertrophy of diabetic
cardiomyopathy. We further showed that calpain activation correlated with increased NFAT and NF-kB activity,
each of which mediates prohypertrophic signaling pathways (18,19,39,40). Indeed, calpain has been identiﬁed as a
key activator of the NF-kB pathway leading to myocardial
hypertrophy in angiotensin-II–induced hypertension (38).
Thus, the dramatic reduction of NF-kB activity levels in
diabetic hearts after Capn4 deletion and calpastatin overexpression underscores the importance of this pathway
in diabetic cardiomyopathy (41). It has been shown that
calpain degrades IkB, the inhibitor of NF-kB, which allows
NF-kB to translocate freely into the nucleus and transcribe
prohypertrophic genes such as b-MHC. We therefore
postulate that inhibition of calpain will increase IkB and
limit NF-kB nuclear translocation, thereby limiting cardiac
hypertrophy in diabetic hearts. Calpain also activates
calcineurin, which is another important mediator of
cardiac hypertrophy (19,20). Activated calcineurin dephosphorylates NFAT, which binds to GATA-4 upon nuclear
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translocation and further augments the transcriptional response leading to myocardial hypertrophy (19). In this
regard, we showed that inhibition of calpain reduced NFAT
activity in diabetic hearts, suggesting that the calcineurin/
NFAT pathway is an additional mechanism by which calpain mediates cardiac hypertrophy in diabetic cardiomyopathy. These results contrast with a recent study that
demonstrated that the NFAT pathway was not involved
in inhibition of myocardial hypertrophy by calpastatin
overexpression in angiotensin-II–induced hypertension (38).
The difference between these two studies suggests that calpain may mediate cardiac hypertrophy via multiple mechanisms depending on the underlying pathological conditions.
Fibrosis is another important hallmark of diabetic cardiomyopathy (1,5,36). It is believed to be a maladaptive response independent of cellular hypertrophy that is
characterized by excess collagen accumulation (1,5,36). We
consistently observed that myocardial collagen deposition
was signiﬁcantly increased in both STZ-induced and OVE26
type 1 diabetic mice. It is noteworthy that both cardiacspeciﬁc deletion of Capn4 and overexpression of calpastatin
reduced collagen deposition and expression levels of
the main components of the ECM, collagens I and III.
This ﬁnding suggests that cardiomyocyte-expressed calpain
may contribute to ﬁbrosis via indirect (paracrine) or direct
mechanisms. However, it is likely that calpain in noncardiomyocytes may also play an important role in myocardial ﬁbrosis in diabetes since Tg-CAST mice displayed
a signiﬁcant reduction in peri vascular ﬁbrosis in response
to angiotensin II stimulation when compared with wild-type
mice (38). Additionally, a signiﬁcant decrease in angiotensin
II–induced synthesis and secretion of collagen occurred in
vascular smooth muscle cells from Tg-CAST mice compared with wild-type mice (38).
Fibroblasts play an important role in ﬁbrosis (42). Cardiac
ﬁbroblasts may differentiate into myoﬁbroblasts, which induce ﬁbroblast proliferation. Our recent study has shown an
increase in myoﬁbroblast marker a-SMA in diabetic hearts
(25), suggesting a possible differentiation of myoﬁbroblasts.
In this regard, we demonstrated a signiﬁcant reduction of
a-SMA expression in diabetic Capn4 knockout hearts. In
line with the downregulation of a-SMA expression, the
number of noncardiomyocytes was reduced in diabetic
Capn42/2 compared with Capn4PZ/PZ mice. Furthermore,
cultured cardiac ﬁbroblasts undergo signiﬁcant hyperplasia in response to high glucose, and that was reduced
by the inhibition of calpain. Fibroblast proliferation is induced by a number of factors, including possibly NF-kB.
Evidence suggests the IkB–NF-kB complex is inﬂuenced by
calpain activation, which may contribute to the development of diabetic cardiomyopathy through the promotion of
ﬁbrosis (43,44). Speciﬁcally, NF-kB is required for the induction of proinﬂammatory cytokines such as TNF-a, which
is also overexpressed in the diabetic heart (25,40). Proinﬂammatory cytokines can further induce expression of
cytokines such as TGF-b1, which is also elevated in the
diabetic heart (25), and is known to be a proﬁbrogenic
inducer (45). Indeed, our data showed that deletion of
Capn4 reduced TNF-a and TGF-b1 expression in the diabetic heart. The proﬁbrogenic effect of these cytokines
may also include MMP activation. Derangement of MMP
activity alters the balance between synthesis and degradation of the ECM resulting in excessive collagen deposition
and reduced structural integrity in the myocardium (35).
Studies have shown upregulation of MMP-9 activity (46) and
downregulation of MMP-2 activity in the diabetic heart (47).
diabetes.diabetesjournals.org
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Inhibition of MMP activity has been suggested to be cardiac
protective in diabetes (48). In the current study, we demonstrated that total MMP activity was increased in both
ﬁbroblasts in vitro in response to high glucose and in the
diabetic heart in vivo, which in both cases was reversed by
calpain inhibition. Speciﬁcally, calpain inhibition also reduced MMP-2 and MMP-9 activities in the diabetic heart.
This ﬁnding reveals a link between calpain and MMPs
in diabetic conditions. Prior work suggests that calpain
induces MMP-9 activity in homocysteine-stimulated cardiac
microvascular endothelial cells (49). Taken together with
our ﬁndings a general role for calpain in the modulating
ECM composition in the heart is likely.
It is currently unknown whether hematopoietic cells contribute to the ﬁbrotic processes in our type 1 diabetes models. The expression of CD68, a marker of macrophage, was
comparable between diabetic Capn42/2 and Capn4PZ/PZ
hearts (Supplementary Fig. 6C), potentially excluding the
involvement of macrophage inﬁltration in the inhibitory
effect of Capn4 deletion in diabetic myocardial ﬁbrosis.
However, we demonstrated that the number of mast cells
was increased in the diabetic heart, which was signiﬁcantly reduced in Capn42/2 compared with Capn4PZ/PZ mice.
Whether this reduction of mast cells plays a role in the
inhibitory effect of Capn4 deletion in diabetic myocardial
ﬁbrosis is beyond the scope of this study and merits future
studies.
In summary, the current study has demonstrated that
targeted inhibition of calpain is protective against hypertrophy and ﬁbrosis, two general hallmarks of diabetic
cardiomyopathy, and preserves myocardial function in
mouse models of type 1 diabetes. These effects of calpain
inhibition may be mediated through NFAT-, NF-kB-, and
MMP-dependent signaling pathways. Cardiac hypertrophy
and deposition of collagen, in particular collagen I and III,
were associated with cardiac dysfunction in diabetes
(1,5,36) and were all restored by calpain inhibition, thereby
supporting the important in vivo functional signiﬁcance
of the calpain/calpastatin system in the diabetic heart.
Therefore, calpain may be a potential therapeutic target for
diabetes heart diseases.
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